Adma Biologics (ADMA) Long-Term Investments (2020 - 2025)

Adma Biologics has reported Long-Term Investments for 6 years, with the latest figure at $8.6 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Investments rose 52.02% year-over-year to $8.6 million; the trailing twelve-month figure through Dec 2025 stood at $8.6 million (up 52.02% YoY), and the FY2025 full-year result was $8.6 million, up 52.02% from the prior year.
• Long-Term Investments for Q4 2025 stood at $8.6 million, down from $8.8 million in the prior quarter.
• The five-year high for Long-Term Investments was $9.1 million in Q2 2025, with the low at $2.5 million in Q2 2021.
• Historically, Long-Term Investments has averaged $5.5 million across 5 years, with a median of $5.2 million in 2024.
• Annual changes were most pronounced in 2021 — Long-Term Investments surged 93.04% — and 2024, when it fell 16.98%.
• Adma Biologics' Long-Term Investments stood at $4.1 million in 2021, then grew by 17.27% to $4.8 million in 2022, then declined by 2.1% to $4.7 million in 2023, then climbed by 21.13% to $5.7 million in 2024, then surged by 52.02% to $8.6 million in 2025.
• The last three Long-Term Investments figures came in at $8.6 million (Q4 2025), $8.8 million (Q3 2025), and $9.1 million (Q2 2025), per Business Quant data.